Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects
Journal of Medicinal Chemistry · 23.03.2023 · 66 (6) · 3746-3784
DOI: 10.1021/acs.jmedchem.2c01695 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 01.03.2023. Verfasst von Maree T Smith und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Analgesics, Opioid, Analgesia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 93 Literaturangaben. Gefördert von: Australian Government, Therapeutic Innovation Australia, University of Queensland.
Abstract (Originalsprache)
The global "opioid crisis" has placed enormous pressure on the opioid ligand discovery community to produce novel opioid analgesics with superior opioid-related adverse-effect profiles compared with morphine. In this Perspective, the multitargeted opioid ligand strategy for the discovery of opioid analgesics with superior preclinical therapeutic indices relative to morphine is reviewed and discussed. Dual-targeted μ-opioid (MOP)/δ-opioid (DOP) ligands in which the in vitro DOP antagonist potency at least equals that of the MOP agonist activity, and are devoid of DOP or κ-opioid (KOP) agonist activity, are sufficiently promising candidates to warrant further investigation. Dual-targeted MOP/NOP partial agonists have superior preclinical therapeutic indices to morphine and/or fentanyl in nonhuman primates and are also considered promising. Based on the poor preclinical and clinical therapeutic indices of cebranopadol, which is a full agonist at MOP, DOP, and NOP receptors and a partial agonist at the KOP receptor, this pharmacologic template should be avoided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
ORCID-Profile: Maree T Smith, Andy Kuo, Mohammad Z Imam, Craig M Williams
Förderung
- Australian Government
- Therapeutic Innovation Australia
- University of Queensland
Zitieren
APA
Smith, M. T., Kong, D., Kuo, A., Imam, M. Z., & Williams, C. M. (2023). Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects. Journal of Medicinal Chemistry, 66(6), 3746-3784. https://doi.org/10.1021/acs.jmedchem.2c01695
Vancouver
Smith MT, Kong D, Kuo A, Imam MZ, Williams CM. Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects. Journal of Medicinal Chemistry. 2023;66(6):3746-3784. doi:10.1021/acs.jmedchem.2c01695
BibTeX
@article{Smith2023,
author = {Smith, Maree T and Kong, Dehui and Kuo, Andy and Imam, Mohammad Z and Williams, Craig M},
title = {Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects},
journal = {Journal of Medicinal Chemistry},
year = {2023},
volume = {66},
number = {6},
pages = {3746--3784},
doi = {10.1021/acs.jmedchem.2c01695}
}
EUVIMED